Pharmaceutical

STAT+: Senators delay start date for possible PBM reforms

Senators drafting reforms to PBMs have delayed their effective date by at least ...

STAT+: Carbon Health blasts a major insurer in rare pub...

Carbon Health blasted health insurer Elevance on Monday for paying it less than ...

In a small new study, scientists working on an AI ‘brai...

Scientists have developed an AI-based system that can "decode" a person's brain ...

STAT+: Pharmalittle: More biotechs are betting on obesi...

A growing number of biotechs are betting on novel mechanisms to treat obesity, h...

Survey: Anti-LGBTQ legislation takes alarming mental-he...

41% of LGBTQ youth seriously considered suicide last year, according to the nati...

STAT+: Astellas acquires Iveric Bio for $5.9B, entering...

Japanese drugmaker Astellas said it would acquire eye drug developer Iveric Bio ...

STAT+: Sam Waksal and Jeremy Levin plot ‘the turnaround...

“I’ve admired the fact that Sam has brought to the market seven separate drugs. ...

Opinion: The apparent poisoning of schoolgirls is just ...

Academic and medical communities in the United States seem uninterested in the h...

STAT+: Beyond Wegovy and Ozempic: Biotechs vie for piec...

You've probably heard of Ozempic and even Mounjaro. But a clutch of startups say...

STAT+: New mega-deal highlights Geisinger’s fall, and r...

Geisinger’s stumbles opened a door for Kaiser Permanente. What does that say abo...

STAT+: Bright Health looks to get out of health insuran...

Bright is looking to sell off the Medicare Advantage plans it manages in Califor...

STAT+: Once bullish on digital health, Orexo hits a wal...

Once bullish on digital health, the pharmaceutical company Orexo has hit a wall ...

STAT Wunderkinds discuss high-impact research, resilien...

At an event highlighting past STAT Wunderkinds, one researcher spoke to the impo...

STAT+: Pharmalittle: Amgen ends two lupus programs; Ill...

In a survey of patient advocacy groups, 52% thought brand-name pharma companies ...

STAT+: Covid-19 burnished pharma’s reputation among pat...

More than half of patient groups surveyed in a new report say pharma isn't doing...

Pennsylvania set to ban supervised drug use sites, in s...

A bill against supervised drug use sites suggests U.S. attitudes toward harm red...